“…The Japanese randomised phase II DEEPER trial (NCT02515734) of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab first line in patients with RAS wt mCRC showed FOLFOXIRI plus cetuximab to be significantly superior to FOLFOXIRI plus bevacizumab in terms of depth of response (DpR), the primary endpoint. 99 There is no phase III evidence, however, to support the use of anti-EGFR mAbs in combination with triplet chemotherapy as demonstrated by the European TRIPLETE trial which failed to show a benefit for FOLFOXIRI plus panitumumab versus FOLFOX plus panitumumab in terms of early tumour shrinkage and DpR. 100 Thus, the word ‘currently’ was added to the original recommendation 4k as per the bold text below, and also Table 1 .…”